Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease

 Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease

Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease

Shots:

  • The P-III CREDENCE study results involves assessing of Invokana (100 mg, qd) vs PBO in patients 4,401 patients in ratio (1:1) with T2D and stage II &III CKD prior treated with ACE inhibitors or angiotensin II receptor blockers
  • The P-III CREDENCE study results: 20% reduction in risk of CV death, heart stroke & death (9.9% vs. 12.2%); 31% reduction in CV death & hospitalization (8.1% vs 11.5%); 39% reduction in hospitalization for heart (4.0% vs 6.4%); reduces the risk ESKD by 31% & 33% in primary and secondary prevention groups respectively
  • Invokana is a therapy for lowering the blood glucose level in adults with T2D and has received FDA’s PR designation and approval for reducing the risk of CV events with T2D in Oct’18

Click here to read full press release/ article | Ref:Janssen | Image: Video Blocks

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post